Coronavirus (COVID19) RTPCR Test

What is an RTPCR test?

RTPCR stands for reversetranscription polymerase chain reaction. It is a laboratory technique used to detect the genetic material (RNA) of the SARSCoV2 virus, the pathogen that causes COVID19. By converting viral RNA into DNA and then amplifying specific DNA sequences, the test can identify the presence of the virus even when only a few copies are present in a sample.

Why RTPCR is considered the gold standard

• Sensitivity: It can detect very low levels of viral RNA, giving a high probability of catching an infection early.
• Specificity: Primers are designed to target unique regions of the SARSCoV2 genome, minimizing falsepositive results from other viruses.
• Regulatory approval: Most health agencies, including WHO and CDC, endorse RTPCR as the primary diagnostic method for COVID19.

Because of these attributes, RTPCR results are used for clinical decisionmaking, travel clearance, and publichealth surveillance.

How the test is performed

1. Sample collection

Samples are usually obtained from the upper respiratory tract using a nasopharyngeal (NP) or oropharyngeal (OP) swab. In some settings, saliva or anterior nasal swabs are accepted, though NP swabs remain the most common for highest viral yield.

2. Transport and storage

The swab is placed in a viral transport medium (VTM) that preserves RNA integrity. Samples should be kept at 28C and processed within 72hours, or frozen at 70C for longer storage.

3. RNA extraction

Laboratories use automated or manual extraction kits to isolate viral RNA from the transport medium. This step removes proteins, enzymes, and contaminants that could inhibit the PCR reaction.

4. Reverse transcription

Extracted RNA is mixed with reverse transcriptase enzymes and primers that bind to specific viral genes (commonly the N, E, or RdRp genes). The enzyme converts RNA into complementary DNA (cDNA).

5. Amplification (PCR)

The cDNA serves as a template for the polymerase chain reaction. Each cycle doubles the amount of target DNA, and fluorescent probes attached to the DNA emit light proportional to the quantity of amplified product. The cycle threshold (Ct) value indicates when fluorescence crosses a preset levela lower Ct means more viral RNA was present in the original sample.

6. Result interpretation

Positive: Detectable fluorescence for the target genes within the assays Ct cutoff (often 38).
Negative: No detectable fluorescence or Ct above the cutoff, plus a valid internal control confirming the assay worked.
Inconclusive/Invalid: Issues with internal control, contamination, or insufficient sample; the test must be repeated.

Understanding Ct values

The Ct (cycle threshold) value is not a direct measure of disease severity, but it can give insight into viral load:

• Ct<20 High viral load, typically early infection or symptomatic phase.
• Ct2030 Moderate viral load, common in most diagnosed cases.
• Ct>30 Low viral load; may represent late infection, resolving illness, or a sample with minimal virus.

Many laboratories report only positive or negative without providing the Ct number to avoid misinterpretation by nonclinical staff.

When is RTPCR testing recommended?

Guidelines may vary by country, but the test is typically advised for:

• Individuals with COVID19 symptoms (fever, cough, loss of taste/smell, etc.).
• Close contacts of a confirmed case, especially if symptoms develop.
• Pretravel screening required by airlines or destination countries.
• Screening in highrisk settings such as hospitals, longterm care facilities, and schools.
• Outbreak investigations to confirm and contain transmission chains.

Advantages and limitations

Advantages

• High analytical sensitivity and specificity.
• Can detect infection before symptoms appear.
• Standardized protocols allow comparison across labs.

Limitations

• Requires specialized equipment and trained personnel.
• Turnaround time varies from a few hours to several days, depending on lab capacity.
• False negatives can occur due to poor sample collection, low viral load, or timing of the test (e.g., testing too early after exposure).
• Higher cost compared with rapid antigen tests.

Comparison with other diagnostic methods

Safety and biosafety considerations

Because the sample may contain live virus, laboratories follow biosafety level 2 (BSL2) practices, including:

• Use of personal protective equipment (PPE) gloves, gown, face shield, N95 respirator.
• Manipulation of specimens within a certified biosafety cabinet.
• Proper decontamination of work surfaces with approved disinfectants (e.g., 70% ethanol, sodium hypochlorite).
• Waste disposal according to infectious materials regulations.

Future directions

Advances aim to make RTPCR faster, cheaper, and more accessible:

• Miniaturized devices: Portable PCR instruments that can deliver results in under an hour.
• Sampleinanswerformat: Direct testing from saliva without RNA extraction, reducing cost and time.
• Multiplex panels: Simultaneous detection of SARSCoV2 and other respiratory pathogens (influenza, RSV) in a single reaction.
• Digital PCR: Provides absolute quantification of viral copies, useful for research and monitoring variants.

Key takeaways

• RTPCR detects viral RNA with high accuracy and remains the benchmark for COVID19 diagnosis.
• Proper sample collection and timely processing are critical for reliable results.
• While highly sensitive, the test is not immune to false negatives; repeat testing may be required if clinical suspicion is high.
• Understanding Ct values can aid clinicians but should not be overinterpreted without context.
• Ongoing innovations are shortening turnaround times and expanding testing capacity worldwide.